The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Biocure Technology Inc stock forecast from 0 analysts, the average analyst target price for Biocure Technology Inc is not available over the next 12 months. Biocure Technology Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biocure Technology Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Biocure Technology Inc’s stock price was USD 0.07000000000000001. Biocure Technology Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Biocure Technology Inc
No recent average analyst rating found for Biocure Technology Inc
Company Overview Biocure Technology Inc
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada. Read Less
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vi...Read More
Frequently Asked Questions About Biocure Technology Inc (BICTF) Stock
Stock Target Advisor's fundamental analysis for Biocure Technology Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on BICTF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BICTF's stock to indicate what its average analyst target is.
BICTF stock's Price/Earning ratio is 7.00.
Our analysis grades BICTF stock's Price / Earning ratio at F. This means that BICTF stock's Price/Earning ratio is above 41% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this BICTF may be fairly valued for its sector
The last closing price of BICTF's stock was USD 0.07.
The most recent market capitalization for BICTF is USD 6.58M.
Unfortunately we do not have enough analyst data on BICTF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biocure Technology Inc's stock.
As per our most recent records Biocure Technology Inc has 0 Employees.
Biocure Technology Inc's registered address is 1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9.
You can get more information about it from Biocure Technology Inc's website at https://www.biocuretech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Biocure Technology Inc (BICTF) Stock
Stock Target Advisor's fundamental analysis for Biocure Technology Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on BICTF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BICTF's stock to indicate what its average analyst target is.
BICTF stock's Price/Earning ratio is 7.00.
Our analysis grades BICTF stock's Price / Earning ratio at F. This means that BICTF stock's Price/Earning ratio is above 41% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this BICTF may be fairly valued for its sector
The last closing price of BICTF's stock was USD 0.07.
The most recent market capitalization for BICTF is USD 6.58M.
Unfortunately we do not have enough analyst data on BICTF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biocure Technology Inc's stock.
As per our most recent records Biocure Technology Inc has 0 Employees.
Biocure Technology Inc's registered address is 1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9.
You can get more information about it from Biocure Technology Inc's website at https://www.biocuretech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BICTF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
